China
· Delayed Price · Currency is CNY BeOne Medicines Statistics
Total Valuation
BeOne Medicines has a market cap or net worth of CNY 209.59 billion. The enterprise value is 199.39 billion.
| Market Cap | 209.59B |
| Enterprise Value | 199.39B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 115.06M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.78% |
| Shares Change (QoQ) | -2.27% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 75.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 85.67 |
| PS Ratio | 6.91 |
| PB Ratio | 8.32 |
| P/TBV Ratio | 8.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 177.27 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -69.59 |
| EV / Sales | 6.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -128.83 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.95 |
| Quick Ratio | 1.64 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.16 |
| Interest Coverage | -18.93 |
Financial Efficiency
Return on equity (ROE) is -11.62% and return on invested capital (ROIC) is -3.86%.
| Return on Equity (ROE) | -11.62% |
| Return on Assets (ROA) | -3.06% |
| Return on Invested Capital (ROIC) | -3.86% |
| Return on Capital Employed (ROCE) | -7.30% |
| Revenue Per Employee | 2.76M |
| Profits Per Employee | -260,485 |
| Employee Count | 11,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.35 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.96% in the last 52 weeks. The beta is 0.35, so BeOne Medicines's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +88.96% |
| 50-Day Moving Average | 235.03 |
| 200-Day Moving Average | 188.38 |
| Relative Strength Index (RSI) | 47.84 |
| Average Volume (20 Days) | 2,628,636 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BeOne Medicines had revenue of CNY 30.34 billion and -2.87 billion in losses. Loss per share was -27.23.
| Revenue | 30.34B |
| Gross Profit | 25.77B |
| Operating Income | -2.02B |
| Pretax Income | -1.89B |
| Net Income | -2.87B |
| EBITDA | -756.96M |
| EBIT | -2.02B |
| Loss Per Share | -27.23 |
Balance Sheet
The company has 18.27 billion in cash and 7.99 billion in debt, giving a net cash position of 10.28 billion.
| Cash & Cash Equivalents | 18.27B |
| Total Debt | 7.99B |
| Net Cash | 10.28B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 25.21B |
| Book Value Per Share | 233.50 |
| Working Capital | 13.73B |
Cash Flow
In the last 12 months, operating cash flow was 1.18 billion and capital expenditures -2.73 billion, giving a free cash flow of -1.55 billion.
| Operating Cash Flow | 1.18B |
| Capital Expenditures | -2.73B |
| Free Cash Flow | -1.55B |
| FCF Per Share | n/a |
Margins
Gross margin is 84.94%, with operating and profit margins of -6.67% and -9.44%.
| Gross Margin | 84.94% |
| Operating Margin | -6.67% |
| Pretax Margin | -6.22% |
| Profit Margin | -9.44% |
| EBITDA Margin | -2.50% |
| EBIT Margin | -6.67% |
| FCF Margin | n/a |
Dividends & Yields
BeOne Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.78% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.37% |
| FCF Yield | -0.74% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |